Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor alpha Redirected T Cells for Recurrent High Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer

Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor alpha Redirected T Cells for Recurrent High Grade Serous Ovarian  Fallopian Tube  or Primary Peritoneal Cancer

Brief description of study

This is a Phase I study evaluating the safety and feasibility of intraperitoneal administered lentiviral transduced MOv19-BBz CAR-T cells in 4 cohorts with or without cyclophosphamide + fludarabine in a 3+3 dose escalation design. Up to 18 evaluable subjects will be treated.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    TBD
  • Age: - 99 Years
  • Gender: All


Updated on 09 Mar 2024. Study ID: 830111
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center